tirzepatide ckd trial Effects of on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT Utilization Trends of Dual GIP/GLP-1

Fluid intake

14 Both studies were limited by relatively short follow-up among the included trials, narrow systemic inclusion criteria, limited information on baseline diabetic retinopathy status and, most important, inadequate and non-rigorous methodologies for diabetic retinopathy evaluation

The clinician's job is to hold that line and to refer questions of selection, evidence interpretation, and compliant sourcing to structured education rather than forum threads

In the Phase 2 clinical trial published in the New England Journal of Medicine, participants receiving the highest dose of retatrutide (12mg weekly) lost an average of 24.2% of their body weight over 48 weeks